257O - Intercontinental cooperative non-Hodgkin T-cell lymphoma prospective registry study in Asia: ICT study

Background

The peripheral T-cell lymphoma (PTCLs) are uncommon and regionally heterogeneous malignancies. However, most studies have been conducted individually in each country, there was no opportunity to analyze the incidence across Asia comprehensively. Besides, the consensus for the treatment of T-cell NHLs has not been established. Thus, we conducted an Asian-specific study to determine the incidence of T-cell NHLs and to assess treatments commonly agreed by the majority.

Methods

We performed a multinational-multicenter, prospective registry study for adult patients with PTCLs. Six countries and 32 institutes in the Republic of Korea, China, Taiwan, Singapore, and Indonesia participated in the ICT study between April. 2016, and February. 2019.

Results

A total of 486 cases were registered. Regardless of subtypes, the median age was 57 (range 19-89) years, and 60% of men had more than women. The patients in stage 3 or 4 were 57.4%. The most prevalent subtype was ENKTL (28.6%), with the second most common subtype being AITL (24.7%), followed by PTCL-NOS (20.8%). The median PFS and OS were 21.1 months and 83.6 months. The PFS and OS for ALK-positive ALCL were superior. In frontline treatment, localized ENKTL patients who received chemoradiotherapy demonstrated superior ORR and PFS (P-value = 0.03) compared to chemotherapy alone. Advanced stage ENKTL who received upfront Auto-SCT also achieved superior outcomes (P-value=0.04). Among patients with PTCL-NOS, AITL, and ALCL, they were treated dominantly with CHOP and CHOEP. However, there was no difference in the survival benefit depending on regimens (CHOP-like vs. CHOEP like, vs. others, P-value = 0.68). Patients who underwent Auto-SCT showed better survival outcomes (P-value= 0.02), but it was not the influence of upfront Auto-SCT (P-value=0.98). In the salvage setting, the efficacy of cytotoxic chemotherapy was disappointed, and none of the salvage strategies is showing superiority.

Conclusions

We identified the relative incidence of T-cell lymphoma and the survival outcomes across Asia. Although the registration of patients is likely to be biased due to the large number of patients registered in some countries, the ICT study was meaningful as a first PTCLs registry study in Asia.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.